DTG + RPV now recommended by DHHS and EACS in treatment guidelines1,2
DHHS Guidelines, October 2017
- DTG + RPV receives AI recommendation* for switching suppressed patients1
*Strong recommendation based on 1 or more randomised trials with clinical outcomes and/or validated laboratory endpoints.1
EACS Guidelines, October 2017
- DTG + RPV included as a switch strategy for virologically suppressed patients.2
References:
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 17, 2017. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed February 12, 2018.
- European AIDS Clinical Society. Guidelines. Version 9.0. October 2017. http://www.eacsociety.org/files/guidelines_9.0-english.pdf. Accessed February 12, 2018.
JULUCA is owned by or licensed to the ViiV Healthcare group of companies.